Abcam, ab257617, Human PTPN1 (PTP1B) knockout HeLa cell lysate

Size: 1Kit
PTPN1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and 1 bp insertion in exon 4 and Insertion of the selection cassette in exon 4.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 4 and 1 bp insertion in exon 4 and Insertion of the selection cassette in exon 4.,
Disease:Adenocarcinoma

Product details:
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PTPN1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Protein tyrosine phosphatase 1B (PTP1B) is an enzyme involved in the dephosphorylation of tyrosine residues in proteins. Known also as PTPN1 this protein has a molecular weight of approximately 50 kDa. PTP1B is widely expressed in tissues but is highly present in the liver muscle and adipose tissue. It plays a critical role in regulating signal transduction pathways by removing phosphate groups from phosphotyrosine residues on target proteins. This action generally serves as a 'turn-off' switch for various signaling pathways.
Biological function summary
PTP1B plays important roles in glucose and lipid metabolism. It is not generally considered a part of a complex functioning instead as a singular enzyme. Its main action involves the negative regulation of the insulin signaling pathway by dephosphorylating the insulin receptor as well as its associated substrates. This regulation helps maintain normal levels of insulin sensitivity influencing cellular glucose uptake and metabolism.
Pathways
PTP1B has important functions in the insulin and leptin signaling pathways. It has a regulatory influence in these pathways affecting key metabolic processes. In the insulin signaling pathway PTP1B closely interacts with the insulin receptor as well as with insulin receptor substrates (IRS). Its dephosphorylating activity can lead to decreased insulin sensitivity. In the leptin pathway PTP1B modulates leptin signaling by dephosphorylating the Janus kinase 2 (JAK2) another protein involved in the control of energy balance and metabolism.
Excessive activity of PTP1B links with disorders such as type 2 diabetes and obesity. Overactivity of PTP1B can lead to insulin resistance contributing to the pathogenesis of type 2 diabetes. In obesity PTP1B may interfere with the normal activity of leptin a hormone critical for regulating energy balance. Its interaction with the insulin receptor and JAK2 makes PTP1B a target for therapeutic interventions aimed at improving insulin sensitivity and energy homeostasis.